Remedium Lifecare Ltd Stock Falls to 52-Week Low of ₹0.41

Stock Price Movement and Market Context

On 6 Mar 2026, Remedium Lifecare Ltd’s share price closed at Rs.0.41, down by 2.22% on the day, underperforming its sector by 0.53%. This marks a steep fall from its 52-week high of Rs.1.94, reflecting a year-long decline of 73.74%. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating persistent downward momentum.

In comparison, the broader Sensex index opened lower at 79,658.99 points, down 0.45%, and was trading at 79,681.51 points (-0.42%) during the same session. The Sensex itself is below its 50-day moving average, though the 50DMA remains above the 200DMA, suggesting some underlying market resilience despite short-term weakness.

Financial Performance and Profitability Concerns

Remedium Lifecare Ltd’s financial metrics reveal ongoing challenges. The company reported a sharp decline in net sales, falling by 65.79% in the most recent quarter to Rs.8.58 crores. Profit after tax (PAT) for the nine months ended was negative at Rs.-2.94 crores, representing a deterioration of 92.82%. Earnings before interest, taxes, depreciation and amortisation (EBITDA) remain negative, contributing to a high Debt to EBITDA ratio of -1.00 times, which signals a low capacity to service debt obligations.

The company has posted losses for five consecutive quarters, with profit before tax less other income (PBT less OI) plunging by 293.90% to Rs.-3.18 crores in the latest quarter. This has resulted in a negative return on capital employed (ROCE), underscoring the lack of profitability and capital efficiency.

Long-Term Growth and Operational Trends

Over the past five years, Remedium Lifecare Ltd’s operating profit has shown no growth, registering an annual growth rate of 0%. This stagnation in core earnings highlights the company’s difficulties in expanding its business or improving operational efficiency. The persistent negative EBITDA and declining sales further compound concerns about the company’s long-term viability within the Trading & Distributors sector.

The stock’s performance over the last three years, one year, and three months has consistently lagged behind the BSE500 index, reflecting below-par returns relative to the broader market. This underperformance is mirrored in the company’s Mojo Score of 1.0 and a Mojo Grade of Strong Sell, which was downgraded from Sell on 9 Apr 2024, signalling deteriorating fundamentals and elevated risk.

Valuation and Risk Profile

Remedium Lifecare Ltd is currently trading at valuations that are considered risky when compared to its historical averages. The combination of negative EBITDA, high leverage, and sustained losses has contributed to a cautious outlook from rating agencies and market analysts. The company’s market capitalisation grade stands at 4, indicating a relatively small market cap within its sector, which may contribute to liquidity constraints and volatility in its share price.

Despite the challenging environment, institutional investors have marginally increased their stake by 1.7% over the previous quarter, collectively holding 1.7% of the company’s shares. This participation suggests some level of interest from investors with greater analytical resources, although the overall exposure remains limited.

Summary of Key Metrics

To summarise, Remedium Lifecare Ltd’s key financial and market indicators as of 6 Mar 2026 are as follows:

• Share price: Rs.0.41 (52-week and all-time low)
• Yearly price decline: -73.74%
• Net sales decline (latest quarter): -65.79% to Rs.8.58 crores
• PAT (9 months): Rs.-2.94 crores, down 92.82%
• PBT less other income (latest quarter): Rs.-3.18 crores, down 293.90%
• Debt to EBITDA ratio: -1.00 times
• Mojo Score: 1.0 (Strong Sell)
• Mojo Grade change: Downgraded from Sell to Strong Sell on 9 Apr 2024
• Market cap grade: 4

Sector and Market Comparison

Within the Trading & Distributors sector, Remedium Lifecare Ltd’s performance contrasts sharply with broader market trends. While the Sensex has delivered a positive return of 7.14% over the past year, Remedium’s stock has declined substantially. The sector itself has experienced mixed results, but Remedium’s persistent negative earnings and declining sales place it among the weaker performers.

The company’s share price underperformance relative to sector peers and the broader market is further emphasised by its position below all major moving averages, signalling a lack of upward momentum and continued investor caution.

Conclusion

Remedium Lifecare Ltd’s fall to Rs.0.41, its lowest price in 52 weeks and all time, reflects a combination of sustained financial setbacks, declining sales, and profitability pressures. The company’s negative EBITDA, high leverage, and five consecutive quarters of losses have contributed to a challenging valuation environment. While institutional investors have marginally increased their holdings, the overall market sentiment remains subdued, with the stock continuing to trade below key technical levels and underperforming both its sector and the broader market indices.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today